Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED
- PMID: 39707320
- PMCID: PMC11662558
- DOI: 10.1186/s12955-024-02321-3
Clinical importance of patient-reported outcome measures in severe asthma: results from U-BIOPRED
Abstract
Rationale: Knowledge about the clinical importance of patient-reported outcome measures (PROMs) in severe asthma is limited.
Objectives: To assess whether and to what extent asthma exacerbations affect changes in PROMS over time and asthma-specific PROMs can predict exacerbations in adult patients with severe asthma in usual care.
Methods: Data of 421 patients with severe asthma (62% female; mean age 51.9 ± 13.4 years; mean FEV1 67.5 ± 21.3%pred) from the U-BIOPRED cohort were analyzed. The included PROMs were: Asthma Control Questionnaire (ACQ5); Asthma Quality of Life Questionnaire (AQLQ); Hospital Anxiety and Depression scale (HADS); Epworth Sleepiness Scale (ESS); Medication Adherence Report Scale (MARS); Sino-Nasal Outcomes Test (SNOT20). Participants were assessed at baseline and after 12-18 months of usual care.
Results: PROMs showed very weak to weak correlations with clinical characteristics such as age, body mass index, FEV1, FeNO and eosinophilic cell count. Patients presenting no exacerbations during follow-up showed a statistically significant improvement in all PROMs (except for MARS), whereas individuals experiencing > 2 exacerbations showed a deterioration. Baseline ACQ5 was a predictor of exacerbations with an AUC of 0.590 (95%CI 0.514-0.666).
Conclusions: The association of PROMs with clinical measures was poor in severe asthmatics. Moreover, PROMs were prone to changes in usual care, with exacerbations playing a key role. PROMs need to be systematically evaluated in severe asthma to improve clinical care based on specific patient's needs.
Keywords: Health status; Obstructive pulmonary diseases; Patient outcome assessment.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The medical ethics committee of each participating center of the U-BIOPRED study approved this study. All participants gave written and signed informed consent. Competing interests: The authors declare no competing interests.
References
-
- Global Initiative For Asthma (GINA). Global Strategy for Asthma Management and Prevention 2023. Accessed on [October 1st 2023]; Available from: www.ginasthma.org.
-
- Pavord ID, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350–400. - PubMed
